¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, Á¤º¸¿øº°, À¯Çüº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Intraoperative Neuromonitoring Market Size, Share & Trends Analysis Report By Product, By Source, By Type, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1609545
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 11¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 120 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå ¼ºÀå°ú µ¿Çâ:
¼¼°è ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð´Â 2030³â 46¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 5.97%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ·¯ÇÑ ¼ºÀåÀº ±â¼ú ¹ßÀü, ±â±â ¾ÈÀü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡¿¡ ±âÀÎÇϸç, COVID-19ÀÇ ¹ß»ýÀº ½ÃÀå¿¡ ÀÌÁßÀ¸·Î ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2020³â 3¿ù ¹Ì±¹ ¿Ü°ú ÇÐȸ(ACS)´Â ¹Ì±¹¿¡¼ COVID-19ÀÇ ±Þ¼ÓÇÑ Áõ°¡·Î ÀÎÇØ ¼±ÅÃÀû ¼ö¼úÀÇ Ãà¼Ò, ¿¬±â ¹× Áß´ÜÀ» Á¦¾ÈÇÏ´Â ¼º¸íÀ» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ¼ö¼úÀÇ Ãà¼Ò, ¿¬±â, Áß´ÜÀ» Á¦¾ÈÇÏ´Â ¼º¸íÀ» ¹ßÇ¥Çߴµ¥, ÀÌ´Â ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, Elsevier Àú³Î¿¡ °ÔÀçµÈ ¿¬±¸(±¹Á¦ ÃâÇ÷¼º ³úÁ¹Áß Çùȸ, 2021³â 1¿ù)¿¡ µû¸£¸é, ÀÔ¿ø ÁßÀÎ COVID-19 ȯÀÚÀÇ ÃÖ´ë 36%°¡ ½Å°æÇÐÀû Áõ»óÀ» º¸ÀÏ ¼ö ÀÖÀ¸¸ç, ÇãÇ÷¼º ¹× ÃâÇ÷¼º °æ»ö°ú °ü·ÃµÈ »ç·Ê°¡ ¿©·¯ °Ç ¹ß°ßµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ 2021³â 6¿ù Neurology Online Journal¿¡ °ÔÀçµÈ ¶Ç ´Ù¸¥ ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é COVID-19 ¹ÙÀÌ·¯½º°¡ »õ·Î¿î ½Å°æ ÁúȯÀÇ ¹ßº´¿¡ °ü¿©ÇÒ ¼ö ÀÖÀ½À» ½Ã»çÇß½À´Ï´Ù. »õ·Î¿î ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ º´¿ø ³» »ç¸Á À§ÇèÀÌ Áõ°¡Çϰí Åð¿øÀ²ÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ¯Â¡Àº ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀåÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ½Å°æ¿Ü°ú¼ö¼ú °Ç¼ö Áõ°¡, ¼ö¼úÀÇ °æÁ¦¼º Áõ°¡, ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ Á߿伺 Áõ°¡·Î ÀÎÇØ ÀÌ ½ÃÀåÀº ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ(IONM)Àº Àç¼ö¼ú Ƚ¼ö¸¦ ÁÙÀÌ°í ¼ö¼ú ÈÄ ÇÕº´Áõ°ú ÈÄÀ¯Áõ ¹ß»ýÀ» ÁÙÀÏ ¼ö Àֱ⠶§¹®¿¡ º´¿øÀº ´Ù¾çÇÑ ¼ö¼ú¿¡ Àû¿ëÇϰí ÀÖ½À´Ï´Ù.
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
À¯Çüº°·Î´Â 2024³â º´¿ø ºÎ¹®ÀÌ 52.72%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À̴ ȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó ÀÇ»çµé »çÀÌ¿¡¼µµ IONMÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ º´¿øÀÌ º¹ÀâÇÑ ¼ö¼ú ½Ã IONMÀ» »ç¿ëÇÏ°Ô µÇ¾ú±â ¶§¹®À¸·Î ÃßÁ¤µË´Ï´Ù. À̰ÍÀÌ IONMÀÌ ÀÌ ½ÃÀå¿¡¼ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ´Â ÁÖ¿ä ÀÌÀ¯ÀÔ´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â 49.35%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À¿Í ±â¼ú ¹ßÀüÀÌ ÀÌ·¯ÇÑ ¿ìÀ§ÀÇ ¿äÀÎÀÔ´Ï´Ù.
À¯·´ÀÇ ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È 6.38%ÀÇ CAGR·Î ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óºÎ ½ÃÀå Àü¸Á
°ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ºÐ¼® Åø
¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
Á¦4Àå ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå - ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2018-2030³â
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç° Àü¸Á°ú Áß¿äÇÑ Æ÷ÀÎÆ®
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
Á¦Ç°º°
½Ã½ºÅÛ
½Ã½ºÅÛ ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
ÀÏȸ¿ë
EMG Æ©ºê¿Í Àü±Ø
½ºÆ¼Ä¿ Àü±Ø
ÀÚ±Ø ÇÁ·Îºê
Á¦5Àå ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå - ºÎ¹® ºÐ¼®, Á¤º¸¿øº°, 2018-2030³â
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¤º¸¿ø Àü¸Á°ú Áß¿äÇÑ Æ÷ÀÎÆ®
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Á¤º¸¿ø º¯µ¿ ºÐ¼®
Á¤º¸¿øº°
Àμҽº
Àμҽº ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
¾Æ¿ô¼Ò½Ì
¾Æ¿ô¼Ò½Ì ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦6Àå ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå - ºÎ¹® ºÐ¼®, À¯Çüº°, 2018-2030³â
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : À¯Çü Àü¸Á°ú Áß¿äÇÑ Æ÷ÀÎÆ®
¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®
À¯Çüº°
´Ü¼ÓÀûÀÎ ¸ð´ÏÅ͸µ
´Ü¼ÓÀû ¸ð´ÏÅ͸µ ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ
Áö¼ÓÀû ¸ð´ÏÅ͸µ ½ÃÀå ¸ÅÃâ ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦7Àå ¼ö¼úÁß ½Å°æ ¸ð´ÏÅ͸µ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
Áö¿ª ´ë½Ãº¸µå
½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018³â¿¡¼ 2030³â :
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³ë¸£¿þÀÌ
½º¿þµ§
µ§¸¶Å©
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
È£ÁÖ
Çѱ¹
ű¹
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
±â¾÷ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
ÁÖ¿ä ±â¾÷ °³¿ä
Natus Medical Incorporated
Medtronic
Accurate Monitoring
Neuromonitoring Technologies
NuVasive, Inc.
SpecialtyCare, LLC
Neurosoft
Ambu A/S
Brainlab(Dr. Langer Medical GmbH)
Welcony(Neurosign UK Ltd.)
ksm
¿µ¹® ¸ñÂ÷
Intraoperative Neuromonitoring Market Growth & Trends:
The global intraoperative neuromonitoring market size is expected to reach USD 4.66 billion in 2030 and is anticipated to grow at a CAGR of 5.97% over the forecast period. This growth can be attributed to technological advancements, increasing awareness regarding the safety of the devices, and the growing geriatric population. The COVID-19 outbreak is expected to have a dual impact on the market. In March 2020, the American College of Surgeons (ACS) published a proposal to reduce, postpone, or cancel elective surgeries as COVID-19 cases grew quickly in the U.S., which is expected to hamper growth.
Moreover, according to a research study published in Elsevier journal (International Hemorrhagic Stroke Association; Jan 2021), up to 36% of hospitalized COVID-19 patients might exhibit neurological symptoms, and there were several cases related to ischemic & hemorrhagic infarction. In addition, another recent research study published in Neurology Online Journal in June 2021 proposed that the COVID-19 virus might be responsible for patients acquiring novel neurological diseases. Owing to the growth of new diseases, there is a higher risk of in-hospital mortality and a low discharge rate. These characteristics are expected to result in lucrative growth over the forecast period.
Furthermore, the market is expected to witness growth due to the increasing number & affordability of neurosurgeries and the growing emphasis on patient safety in surgeries. Hospitals are adopting Intraoperative Neuromonitoring (IONM) in a wide spectrum of surgeries, as it reduces the number of revision surgeries and results in fewer postoperative complications & cases of permanent impairment.
Intraoperative Neuromonitoring Market Report Highlights:
By type, the insourced segment accounted for the largest share of 52.72% in 2024. This can be attributed to growing awareness among physicians as well as patients about the benefits of IONM, which results in the hospitals utilizing IONM during complex procedures. This is a key reason for the dominance of insourced IONM in the market
By region, North America accounted for the largest share of 49.35% in 2024. Favorable reimbursement scenarios along with technological advancements can be attributed to this dominance
The intraoperative neuromonitoring market in Europe is anticipated to grow fastest with a CAGR of 6.38% during the forecast period
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Source
1.2.3. Type
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Intraoperative Neuromonitoring Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing demand for IONM in hospitals
3.2.1.2. Technological advancements in intraoperative neuromonitoring systems
3.2.1.3. Increasing prevalence of neurovascular disorders
3.2.2. Market Restraint Analysis
3.2.2.1. Complex regulatory framework
3.2.2.2. Surgery-associated risk
3.3. Intraoperative Neuromonitoring Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Intraoperative Neuromonitoring Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
4.1. Intraoperative Neuromonitoring Market: Product Outlook and Key Takeaways
4.2. Intraoperative Neuromonitoring Market: Product Movement Analysis
4.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Product (USD Million)
4.4. Systems
4.4.1. Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Disposables
4.5.1.1. Disposables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. EMG Tubes And Electrodes
4.5.2.1. EMG Tubes And Electrodes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Sticker Electrode
4.5.3.1. Sticker Electrode Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Stimulating Probes
4.5.4.1. Stimulating Probes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Intraoperative Neuromonitoring Market - Segment Analysis, by Source, 2018 - 2030 (USD Million)
5.1. Intraoperative Neuromonitoring Market: Source Outlook and Key Takeaways
5.2. Intraoperative Neuromonitoring Market: Source Movement Analysis
5.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Source (USD Million)
5.4. Insourced
5.4.1. Insourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Outsourced
5.5.1. Outsourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Intraoperative Neuromonitoring Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)
6.1. Intraoperative Neuromonitoring Market: Type Outlook and Key Takeaways
6.2. Intraoperative Neuromonitoring Market: Type Movement Analysis
6.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Type (USD Million)
6.4. Intermittent Monitoring
6.4.1. Intermittent Monitoring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Continuous Monitoring
6.5.1. Continuous Monitoring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Intraoperative Neuromonitoring Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. Natus Medical Incorporated
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Medtronic
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Accurate Monitoring
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Neuromonitoring Technologies
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. NuVasive, Inc.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. SpecialtyCare, LLC
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Neurosoft
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Ambu A/S
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Brainlab (Dr. Langer Medical GmbH)
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Welcony (Neurosign UK Ltd.)
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
°ü·ÃÀÚ·á